Your browser doesn't support javascript.
loading
Ceramide and sphingosine-1 phosphate in COPD lungs.
Berdyshev, Evgeny V; Serban, Karina A; Schweitzer, Kelly S; Bronova, Irina A; Mikosz, Andrew; Petrache, Irina.
Afiliação
  • Berdyshev EV; Department of Medicine, National Jewish Health, Denver, Colorado, USA.
  • Serban KA; Department of Medicine, University of Illinois Chicago, Chicago, Illinois, USA.
  • Schweitzer KS; Department of Medicine, National Jewish Health, Denver, Colorado, USA.
  • Bronova IA; School of Medicine, Indiana University, Indianapolis, Indiana, USA.
  • Mikosz A; School of Medicine, University of Colorado Denver, Aurora, Colorado, USA.
  • Petrache I; Department of Medicine, National Jewish Health, Denver, Colorado, USA.
Thorax ; 2021 Jan 29.
Article em En | MEDLINE | ID: mdl-33514670
ABSTRACT
Studies of chronic obstructive pulmonary disease (COPD) using animal models and patient plasma indicate dysregulation of sphingolipid metabolism, but data in COPD lungs are sparse. Mass spectrometric and immunostaining measurements of lungs from 69 COPD, 16 smokers without COPD and 13 subjects with interstitial lung disease identified decoupling of lung ceramide and sphingosine-1 phosphate (S1P) levels and decreased sphingosine kinase-1 (SphK1) activity in COPD. The correlation of ceramide abundance in distal COPD lungs with apoptosis and the inverse correlation between SphK1 activity and presence of emphysema suggest that disruption of ceramide-to-S1P metabolism is an important determinant of emphysema phenotype in COPD.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Thorax Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Thorax Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos